Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin B6 and B12 for Antipsychotic-Induced Movement Disorders
NCT03790345Phase 3Unknown
- Start
- Sep 2019
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pyridoxine and vitamin b12 in drug-induced movement disorder (DIMD) (3 arms). Primary endpoints: Simpson-Angus Extrapyramidal Symptoms Scale at 12 weeks, Barnes Akathisia Rating Scale at 12 weeks and 1 more. Status: unknown.
02
Drugs
pyridoxinevitamin b12
03
Conditions
drug-induced movement disorder (DIMD)
Beyond the preview
Go deeper on NCT03790345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790345.